PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8941167-11	1996	Sertindole and risperidone demonstrate polymorphic metabolism characteristics mirroring the CYP 2D6 phenotype.	sertindole	0-10	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	92-99	
8941167-12	1996	The inhibitory potentials of sertindole at CYP 2D6 and CYP 3A are modest and not likely to be of clinical significance.	sertindole	29-39	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	43-50	
8941167-13	1996	However, in those patients taking CYP 2D6 inhibitors or in those who are genotypic poor metabolizers, concentrations achieved by sertindole and its metabolites might result in moderate inhibition of CYP 3A.	sertindole	129-139	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	34-41	
20856845-3	2010	Sertindole undergoes extensive hepatic metabolism by the cytochrome P450 isoenzymes CYP2D6 and CYP3A4 and has an elimination half-life of approximately three days.	sertindole	0-10	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	84-90	
17214606-7	2007	Quetiapine is metabolized by CYP3A4, while sertindole and aripiprazole are metabolized by CYP2D6 and CYP3A4.	sertindole	43-53	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	90-96	
17458045-14	2007	(6) Sertindole is metabolised by cytochrome P450 isoenzymes CYP 2D6 and CYP 3A4, hence a high risk of pharmacokinetic interactions.	sertindole	4-14	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	60-67	
15572279-5	2005	Thioridazine (Ki=15 microM) was the most potent inhibitor of the rat CYP2D among the drugs studied, whose effect was more pronounced than that of the other neuroleptics tested: phenothiazines (Ki=18-23 microM), haloperidol (Ki=32 microM), sertindole (Ki=51 microM) or risperidone (Ki=165 microM).	sertindole	239-249	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	69-74	
10422890-7	1999	Quetiapine is metabolised by CYP3A4 and sertindole by CYP2D6.	sertindole	40-50	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60	
9562230-6	1998	Although terfenadine is a substrate for CYP3A (cytochrome P-450 3A), while sertindole is a substrate for both CYP2D6 and CYP3A4, the results in this study suggest that sertindole, at a clinical dose, is not an inhibitor of the metabolism of terfenadine.	sertindole	75-85	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	110-116	
9562230-6	1998	Although terfenadine is a substrate for CYP3A (cytochrome P-450 3A), while sertindole is a substrate for both CYP2D6 and CYP3A4, the results in this study suggest that sertindole, at a clinical dose, is not an inhibitor of the metabolism of terfenadine.	sertindole	168-178	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	110-116	
9218930-7	1997	The total fraction of the sertindole dose removed by dialysis was less than 0.1% Subjects with B/B genotype (n = 2) for CYP2D6 were associated with a distinctly lower clearance of sertindole (6.3 vs 25.3 1.h-1) than subjects with wt/wt genotype for CYP2D6.	sertindole	26-36	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	120-126	
9218930-7	1997	The total fraction of the sertindole dose removed by dialysis was less than 0.1% Subjects with B/B genotype (n = 2) for CYP2D6 were associated with a distinctly lower clearance of sertindole (6.3 vs 25.3 1.h-1) than subjects with wt/wt genotype for CYP2D6.	sertindole	180-190	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	120-126